Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pharmacologic inhibition of MIF nuclease: A new treatment paradigm to treat cell death

1 Sept 2022

Abstract excerpt

Neurodegenerative diseases and disorders are characterized by the loss of neurons via numerous mechanisms, resulting in observable phenotypes, such as memory impairment, motor dysfunction and more. Discoveries in neurodegeneration research are driving forward biomarker and therapeutic development. However, at this time, there are no curative or disease-slowing treatments for neurological disorders, including...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to PARP inhibition in cancer therapy
Share to Trace Elements in Health
Share to Viral Infections and Immunology Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 36125899
DOI: 10.1002/ctm2.1044

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacologic inhibition of MIF nuclease: A new treatment paradigm to treat cell deathPMID 36125899Read ↗

Poly (ADP-Ribose) polymerase 1 and parthanatos in neurological diseases: From pathogenesis to therapeutic opportunitiesSemantic proximity Read ↗

A nuclease that mediates cell death induced by DNA damage and poly(ADP-ribose) polymerase-1.Semantic proximity Read ↗

Emerging role of PARP‐1 and PARthanatos in ischemic strokeSemantic proximity Read ↗

Parthanatos: mitochondrial‐linked mechanisms and therapeutic opportunitiesSemantic proximity Read ↗

Poly (ADP-ribose) in the pathogenesis of Parkinson's diseaseSemantic proximity Read ↗

Parthanatos, a messenger of deathSemantic proximity Read ↗

Mitochondrial and Nuclear Cross Talk in Cell DeathSemantic proximity Read ↗

Exploring the role of parthanatos in CNS injury: Molecular insights and therapeutic approachesSemantic proximity Read ↗

Therapeutic Potentials of Poly (ADP‐Ribose) Polymerase 1 (PARP1) Inhibition in Multiple Sclerosis and Animal Models: Concept RevisitingSemantic proximity Read ↗

Histone H1.2 Dependent Translocation of Poly (ADP-ribose) Initiates ParthanatosSemantic proximity Read ↗

Nuclear poly(ADP-ribose) activity is a therapeutic target in amyotrophic lateral sclerosis.Semantic proximity Read ↗

The PARP Side of the Nucleus: Molecular Actions, Physiological Outcomes, and Clinical TargetsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.